AAAAAA

   
Results: 1-11 |
Results: 11
FLOW CYTOMETRIC DETERMINATION OF GANCICLOVIR SUSCEPTIBILITIES OF HUMAN CYTOMEGALOVIRUS CLINICAL ISOLATES
Authors: MCSHARRY JM LURAIN NS DRUSANO GL LANDAY A MANISCHEWITZ J NOKTA M OGORMAN M SHAPIRO HM WEINBERG A REICHELDERFER P CRUMPACKER C
Citation: Jm. Mcsharry et al., FLOW CYTOMETRIC DETERMINATION OF GANCICLOVIR SUSCEPTIBILITIES OF HUMAN CYTOMEGALOVIRUS CLINICAL ISOLATES, Journal of clinical microbiology, 36(4), 1998, pp. 958-964
PREFACE TO THE 1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS/
Authors: MASUR H KAPLAN JE HOLMES KK BAKER AC BARR D BENSON C BROSGART C CHAISSON R COOPER E CRUMPACKER C DECKER C DREW L EISINGER R ELSADR W FREEDBERG K GOLDBERGER M GORDIN F GREAVES W GROSS P HAFNER R HAVLIR D HORSBURGH R JABS D KITAHATA M KOVACS J MARTONE W MAYERS D MELNICK D MOFENSON L NEATON J NELSON C OLDFIELD E PHAIR J POLIS M POLSKY B POWDERLY W RIMLAND D SLOAND E SOLOMON L SPECTOR S SPERLING R TRAPNELL CB VANDYKE R WHITLEY R WRIGHT T BELAY E BUTLER JC CASTRO KG DYKEWICZ C EDLIN BR ELLERBROCK T HAJJEH RA JAFFE HW JURANEK D MCNEIL M MILLER B PELLETT PE REEVES W SCHLUTER WW SPIEGEL RA STEWART JA STYRT B VERNON SD WARD J
Citation: H. Masur et al., PREFACE TO THE 1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS/, Clinical infectious diseases, 25, 1997, pp. 299
1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - DISEASE-SPECIFIC RECOMMENDATIONS/
Authors: MASUR H KAPLAN JE HOLMES KK ARMSTRONG D BAKER AC BARR D BENSON C BROSGART C CHAISSON R COOPER E CRUMPACKER C DECKER C DREW L EISINGER R ELSADR W FREEDBERG K GOLDBERGER M GORDIN F GREAVES W GROSS P HAFNER R HAVLIR D HORSBURGH R JABS D KITAHATA M KOVACS J MARTONE W MAYERS D MELNICK D MOFENSON L NEATON J NELSON C OLDFIELD E PHAIR J POLIS M POLSKY B POWDERLY W RIMLAND D SLOAND E SOLOMON L SPECTOR S SPERLING R TRAPNELL CB VANDYKE R WHITLEY R WRIGHT T BELAY E BUTLER JC CASTRO KG DYKEWICZ C EDLIN BR ELLERBROCK T HAJJEH RA JAFFE HW JURANEK D MCNEIL M MILLER B PELLETT PE REEVES W SCHLUTER WW SPIEGEL RA STEWART JA STYRT B VERNON SD WARD J
Citation: H. Masur et al., 1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - DISEASE-SPECIFIC RECOMMENDATIONS/, Clinical infectious diseases, 25, 1997, pp. 313-335
A PHASE-II STUDY OF RECOMBINANT HUMAN INTERFERON-(ALPHA-2A) AND ZIDOVUDINE IN PATIENTS WITH AIDS-RELATED KAPOSIS-SARCOMA
Authors: FISCHL MA FINKELSTEIN DM HE WL POWDERLY WG TRIOZZI PL STEIGBIGEL RT MAIEWSKI S DALE E MILLAR L GOULD M RATNER L PARA MF GOWER R TENZLER R FUHRER J MILDVAN D MALAMUD SC DEZUBE B CHAPMAN B CRUMPACKER C ISRAEL HB FEINBERG J HOOD A RAINES CP MILES SA MITSUYASU RT CARDEN J MCMAHON D PAZIN G SCHULOF RS CORTLESS JL LELACHEUR SF EHMANN WC EYSTER ME MCKINLEY GF GRIECO MH KOLATCH B BENNETT JM RYBAK ME CHEESEMAN SH KOUP RA DIAMOND A
Citation: Ma. Fischl et al., A PHASE-II STUDY OF RECOMBINANT HUMAN INTERFERON-(ALPHA-2A) AND ZIDOVUDINE IN PATIENTS WITH AIDS-RELATED KAPOSIS-SARCOMA, Journal of acquired immune deficiency syndromes and human retrovirology, 11(4), 1996, pp. 379-384
THE PHARMACOLOGICAL PROFILE OF FAMCICLOVIR
Authors: CRUMPACKER C
Citation: C. Crumpacker, THE PHARMACOLOGICAL PROFILE OF FAMCICLOVIR, Seminars in dermatology, 15(2), 1996, pp. 14-26
CORRELATION OF PLASMA HIV-1 RNA LEVEL AND DEVELOPMENT OF RESISTANCE MUTATIONS TO AZT AND DDI WITH DISEASE PROGRESSION IN PATIENTS WITH ADVANCED HIV-1 DISEASE AND LITTLE OR NO AZT THERAPY
Authors: CRUMPACKER C WELLES S YENLIEBERMAN B DEMETER L JAPOUR A SMEATON L JOHNSON V KURITZES D DAQUILA R REICHELDERFER P RICHMAN D REICHMAN R MCLAREN C TODD J KWOK S COOMBS R JACKSON B
Citation: C. Crumpacker et al., CORRELATION OF PLASMA HIV-1 RNA LEVEL AND DEVELOPMENT OF RESISTANCE MUTATIONS TO AZT AND DDI WITH DISEASE PROGRESSION IN PATIENTS WITH ADVANCED HIV-1 DISEASE AND LITTLE OR NO AZT THERAPY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 42-42
PENTAMIDINE AEROSOL VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PNEUMOCYSTIS-CARINII IN ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME
Authors: MONTGOMERY AB FEIGAL DW SATTLER F MASON GR CATANZARO A EDISON R MARKOWITZ N JOHNSON E OGAWA S ROVZAR M UDEM SA EDEN E HYSLOP N CHEUNG TW KESSLER H MILDVAN D GIRON JA ETTINGER N CRUMPACKER C FRAME P STEIGBIGEL N VANDERHORST C HIRSCH M LEDERMAN MM HEWITT RG FALLAT R FARBER HW SACKS HS EISMAN SA LUCE JM BOYLAN T ADAMS M FEINBERG J HOPEWELL PC
Citation: Ab. Montgomery et al., PENTAMIDINE AEROSOL VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PNEUMOCYSTIS-CARINII IN ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME, American journal of respiratory and critical care medicine, 151(4), 1995, pp. 1068-1074
ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS
Authors: DREW WL IVES D LALEZARI JP CRUMPACKER C FOLLANSBEE SE SPECTOR SA BENSON CA FRIEDBERG DN HUBBARD L STEMPIEN MJ SHADMAN A BUHLES W
Citation: Wl. Drew et al., ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS, The New England journal of medicine, 333(10), 1995, pp. 615-620
COMBINATION OF GANCICLOVIR AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS
Authors: HARDY D SPECTOR S POLSKY B CRUMPACKER C VANDERHORST C HOLLAND G FREEMAN W HEINEMANN MH SHARUK G KLYSTRA J CHOWN M
Citation: D. Hardy et al., COMBINATION OF GANCICLOVIR AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS, European journal of clinical microbiology & infectious diseases, 13, 1994, pp. 190000034-190000040
PHASE-II DOSE-RANGING TRIAL OF FOSCARNET SALVAGE THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS INTOLERANT OF OR RESISTANT TO GANCICLOVIR (ACTG PROTOCOL 093)
Authors: JACOBSON MA WULFSOHN M FEINBERG JE DAVIS R POWER M OWENS S CAUSEY D HEATHCHIOZZI ME MURPHY RL CHEUNG TW DIETERICH DT SPECTOR SA MCKINLEY GF PARENTI DM CRUMPACKER C NISHIMOTO B LEEDOM JM KRAMER F COHEN C LOFTUS J KESSLER HA POTTAGE JC BENSON CA PHAIR JP GERITS P CHUSID E SACKS HS FRIEDBERG D CURRANKRIKORIAN K VALENTINE FT MENG TC FREEMAN WR MEIXNER L RICHMAN D ODONNELL JJ KIMBRELL C BOGGIO K LARSON J WHITMORE PV SIMON GL LELACHEUR S FIFE K ZWICKL B RELUE J STEIGBIGEL RT FUHRER J DONLON W BURK RA PORTMORE AC WEISSBACH NE HOOTON TM HOLZWORTH P DAVISON S COLLIER AC POWDERLY WG KLEBERT M ROYAL M SEYFRIED W SQUIRES KC WEISS W BARBACCI M BECKER RL JABS D BARTLETT JG PARA MF JONES M NEIDIG JL FASS RJ VANDERHORST C KYLSTRA J RAASCH R BLOODGOOD K WOLITZ R KIRK S ROLFE L PATRONEREESE J BARTLETT JA WASKIN HA WILLIAMS DK SHIP KW KAHL P ASSAYKEEN T KAROL C MARTINMUNLEY S SUMNER P
Citation: Ma. Jacobson et al., PHASE-II DOSE-RANGING TRIAL OF FOSCARNET SALVAGE THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS INTOLERANT OF OR RESISTANT TO GANCICLOVIR (ACTG PROTOCOL 093), AIDS, 8(4), 1994, pp. 451-459
USE OF VIROLOGICAL ASSAYS FOR DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS IN CLINICAL-TRIALS - RECOMMENDATIONS OF THE AIDS CLINICAL-TRIALS GROUP VIROLOGY COMMITTEE
Authors: HAMMER S CRUMPACKER C DAQUILA R JACKSON B LATHEY J LIVNAT D REICHELDERFER P
Citation: S. Hammer et al., USE OF VIROLOGICAL ASSAYS FOR DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS IN CLINICAL-TRIALS - RECOMMENDATIONS OF THE AIDS CLINICAL-TRIALS GROUP VIROLOGY COMMITTEE, Journal of clinical microbiology, 31(10), 1993, pp. 2557-2564
Risultati: 1-11 |